Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients

Published:2011-09-26 Issue:6 Volume:47 Page:874-876
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Ianotto J-C,Tempescul A,Yan X,Delepine P,Le Calloch R,Hardy E,Eveillard J-R,Mugnier N,Berthou C,Guillerm G

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2011189.pdf

Reference10 articles.

1. Kuhlmann M, Covic A . The protein science of biosimilars. Nephrol Dial Transplant 2006; 21: v4–v8.

2. Mellstedt H, Niederwieser D, Ludwig H . The challenge of biosimilars. Ann Oncol 2008; 19: 411–419.

3. Niederwieser D, Schmitz S . Biosimilar agents in oncology/haematology: from approval to practice. Eur J Haematol 2011; 86: 277–288.

4. Ferro HH, Juni M, Bello R, Vidal A, Diez RA, Pavlovsky S . Utilization study of filgrastim (neutromax) during autologous haematopoietic precursor transplantation for myeloma and lymphoma patients. Transfus Apher Sci 2009; 41: 87–93.

5. Ianotto JC, Tempescul A, Delepine P, Guillerm G, Hardy E, Eveillard JR et al. Delayed G-CSF stimulation after PBSCT does not seem to modify the biological parameters of bone marrow recovery. Am J Hematol 2011; 86: 351–352.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost efficiency and effectiveness of biosimilar filgrastim in autologous transplant;Bone Marrow Transplantation;2021-11-30

2. Real World Clinical Experience of Biosimilar G-CSF (Grastofil) for Autologous Peripheral Blood Stem Cell Mobilization: Single Center Experience in Canada Following Early Adoption;Current Oncology;2021-04-22

3. ERKRANKUNGEN DES BLUTES UND DES GERINNUNGSSYSTEMS, SOLIDE TUMOREN UND PRINZIPIEN DER INTERNISTISCHEN ONKOLOGIE;Rationelle Diagnostik und Therapie in der Inneren Medizin;2020

4. Safety and efficacy of alternating treatment with EP2006, a filgrastim biosimilar, and reference filgrastim: a phase III, randomised, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy;ANN ONCOL;2018

5. Biosimilars of filgrastim in autologous stem cell transplantation: certain differences for myeloma patients only;Leukemia & Lymphoma;2017-02-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3